Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12282
Title: Effect of testosterone treatment on constitutional and sexual symptoms in men with type 2 diabetes in a randomized, placebo-controlled clinical trial.
Austin Authors: Gianatti, Emily J;Dupuis, Philippe;Hoermann, Rudolf;Zajac, Jeffrey D ;Grossmann, Mathis 
Affiliation: Department of Medicine (E.J.G., P.D., R.H., J.D.Z., M.G.), Austin Health, University of Melbourne, and Endocrine Unit (E.J.G., P.D., J.D.Z., M.G.), Austin Health, Heidelberg 3084, Australia
Issue Date: 30-Jun-2014
Publication information: The Journal of Clinical Endocrinology and Metabolism 2014; 99(10): 3821-8
Abstract: The objective of the study was to assess the effect of T treatment on constitutional and sexual symptoms in men with type 2 diabetes (T2D).This was a randomized double-blind, parallel, placebo-controlled trial.The study was conducted at a tertiary referral center.Men aged 35-70 years with T2D, a hemoglobin A1c less than 8.5%, and a total T level less than 12.0 nmol/L (346 ng/dL) with mild to moderate aging male symptoms and erectile dysfunction.Eighty-eight participants were randomly assigned to 40 weeks of im T undecanoate (n = 45) or matching placebo (n = 43).Constitutional symptoms using the aging male symptoms (AMS) score, sexual desire (question 17 AMS score), and erectile function (International Index of Erectile Function-5).T treatment did not substantially improve aging male symptoms [mean adjusted difference (MAD) in change over 40 weeks across the T and placebo groups in AMS total score, -0.9 (95% confidence interval [CI] -4.1, 2.2), P = .67] or sexual desire [MAD in question 17 AMS, -0.3 (95% CI -0.8, 0.2), P = .17]. Although compared with placebo, erectile function in men assigned to T was reduced [MAD in International Index of Erectile Function abridged version 5, -2.0 (95% CI -3.4, -0.6), P < .02], there was no significant difference between baseline and 40-week International Index of Erectile Function abridged version 5 scores if both groups were analyzed separately. At baseline, symptoms were worse in men with depression and microvascular complications but did not correlate with T levels.In this trial, T treatment did not substantially improve constitutional or sexual symptoms in obese, aging men with T2D with mild to moderate symptoms and modest reduction in T levels typical for the vast majority of such men.
Gov't Doc #: 24978674
URI: https://ahro.austin.org.au/austinjspui/handle/1/12282
DOI: 10.1210/jc.2014-1872
Journal: The Journal of Clinical Endocrinology and Metabolism
URL: https://pubmed.ncbi.nlm.nih.gov/24978674
Type: Journal Article
Subjects: Adult
Aged
Aging
Androgens.administration & dosage.adverse effects.blood
Depression.complications
Diabetes Mellitus, Type 2.complications
Double-Blind Method
Erectile Dysfunction.drug therapy.etiology
Hormone Replacement Therapy.adverse effects.methods
Humans
Libido.drug effects
Male
Middle Aged
Obesity.complications
Placebos
Testosterone.administration & dosage.adverse effects.analogs & derivatives.blood
Treatment Outcome
Appears in Collections:Journal articles

Show full item record

Page view(s)

26
checked on Jul 15, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.